Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Infliximab 5 mg/kg and purine analogues vs purine analogues

Clinical remission · Patients with active Crohn's disease

Infliximab 5 mg/kg and purine analogues probably leads to higher clinical remission as defined by the studies at weeks 24–26 compared with purine analogues alone (moderate certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1.92 [1.59, 2.32]
4 studies · 630 participants
Moderate

Infliximab 5 mg/kg and purine analogues vs purine analogues

Clinical response as defined by the studies at week 26 · Patients with active Crohn's disease

Infliximab 5 mg/kg and purine analogues probably leads to higher clinical response as defined by the studies at week 26 compared with purine analogues alone (moderate certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1.64 [1.31, 2.05]
2 studies · 355 participants
Moderate

Infliximab 5 mg/kg and purine analogues vs purine analogues

Withdrawals due to adverse events · Patients with active Crohn's disease

Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.87 [0.63, 1.21]
4 studies · 603 participants
Low